Premium
Serum HB sAg kinetics and usefulness of interferon‐inducible protein 10 serum in HB eAg‐negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate
Author(s) -
Papatheodoridis G.,
Triantos C.,
Hadziyannis E.,
Zisimopoulos K.,
Georgiou A.,
Voulgaris T.,
Vlachogiannakos I.,
Nikolopoulou V.,
Manolakopoulos S.
Publication year - 2015
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12434
Subject(s) - hbsag , medicine , tenofovir , gastroenterology , hbeag , chronic hepatitis , interferon , immunology , hepatitis b virus , virus , human immunodeficiency virus (hiv)
Summary The kinetics of serum HB sAg and interferon‐inducible protein 10 ( IP 10) levels in patients with chronic hepatitis B infection treated with tenofovir are unclear. We evaluated the changes of HB sAg levels and the predictability of IP 10 for HB sAg decline in 160 HB eAg‐negative patients receiving tenofovir for ≥12 months. Serum samples taken before and at 6, 12, 24, 36 and 48 months after tenofovir were tested for HB sAg levels. In 104 patients, serum samples before tenofovir were tested for IP 10 levels. Compared to before tenofovir, HB sAg levels decreased by a median of 0.08, 0.11, 0.24, 0.33 and 0.38 log 10 IU / mL at 6, 12, 24, 36 and 48 months, respectively ( P < 0.001). HB sAg kinetics did not differ between nucleos(t)ide analogue(s) naive and experienced patients. The 12‐, 24‐, 36‐ and 48‐month cumulative rates of ≥0.5 log 10 HB sAg decline were 8%, 16%, 24% and 41% and of HB sAg ≤100 IU/ mL were 9%, 12%, 14% and 18%, respectively. The only factor associated with HB sAg ≤100 IU / mL was lower HB sAg levels before tenofovir ( P < 0.001), while HB sAg decline ≥0.5 log 10 was associated with higher IP 10 levels ( P = 0.002) and particularly with IP 10 > 350 pg/mL ( P < 0.001). In conclusion, tenofovir decreases serum HB sAg levels in both nucleos(t)ide analogue(s) naive and experienced patients with HB eAg‐negative chronic hepatitis B infection. After 4 years of therapy, HB sAg ≤100 IU / mL can be achieved in approximately 20% of patients, particularly in those with low baseline HB sAg levels. HB sAg decline is slow (≥0.5 log 10 in 40% of patients after 4 years) and is associated only with higher baseline serum IP 10 levels.